If youre bullish on oil, then Continental Resources (CLR) is the stock for you. I believe the company will likely significantly grow its earnings in 2018 due to higher realized prices and around 20% production growth. Meanwhile the company, which burned cash flows in 2017, will likely report str
Small cap diabetes stocks Oramed Pharmaceuticals, Inc (NASDAQ: ORMP), Senseonics Holdings (NYSEMKT: SENS) and Cell MedX Corp (OTCQB: CMXC) might not immediately come to mind when you think of the disease. However, theres plenty of room in the market place for players of all sizes. Just consider some quick statistics about diabetes compiled by Cell MedX Corp:
Succeeding 13 years of R&D with a commercial-level rare disease drug, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) tees up to deliver on the latter half of its promise to provide the world with a DMD cure for sufferers that may be amenable to Exon 51 skipping, and otherwise. A result that would facilitate the first cure for DMD and sizable growth potential.
Today, investors have an incredible opportunity to earn double-digit percentage rates of income. You simply have to look past conventional investments like bonds and mutual funds… Instead, look at unusual income plans like "Digital Utilities." As I'll show you today, this plan is paying out safe income streams of 15% or more… Traditional utility stocks....More>>>
In this article, I make an in-depth analysis of Ally Financial, Inc. (NYSE:ALLY) and argue that this lending and savings institution is uniquely overexposed to the automotive industry through dealer networks, commercial lending, retail auto lending, and subprime auto lending. As part of my thesis, I argue that retail auto sales are currently at their peak as some industry-wide....More>>>
Barclays analyst Jason Goldberg and team have “long been attracted to” shares of JPMorgan Chase (JPM), even before news that CEO Jamie Dimon spent $26 million dollars to buy shares in the mega-bank. With JPMorgan’s investor day coming up on Feb. 23, they explain why:
Photo: Michael Nagle/Bloomberg
We have long been attracted to the shares of JPMorgan, given....More>>>
Money Morning Director of Technology & Venture Capital Research Michael Robinson is still a big fan of Bitcoin and many of the other cryptocurrencies out there. But he acknowledges that they are not for everyone.
This article is reprinted by permission from NextAvenue.org.
Money is the top cause of stress in the U.S., the American Psychological Association reports, and the leading driver of stress in the workplace, according to studies by the National Business Group on Health, Aon Hewitt, PwC and
You buy a stock for the long haul...
It's a great business. It trades at a great price. And you know its upside potential is huge.
For one reason or another, investors don't see the stock for what it is – a fantastic value.
So you take a medium- to large-siz
While most investors are trying to wrap their head around the soaring price of Bitcoin, I'm more focused on its underlying technology (blockchain) and its impact on the future of banking. Blockchain is here to stay and Bank of America (NYSE:BAC) is staking its claims.
On Dec. 20, 2017, the shares of Portola Pharmaceuticals (NASDAQ:PTLA), a bioscience specializing in the innovation and commercialization of drugs to treat blood disorders and cancers increased $4.13 to $55.12 (8.09% profits for traders) as of 2:01 pm EST. Previously, in part I and II r